Sarah W

[Yo-Yo Ma @YoYo_Ma]

Wishing you all a happy 2022.

[Sarah W @swashkowitz]

@BirdCentralPark southwest portion of the Reservoir

[Sarah W @swashkowitz]

@BirdCentralPark

[Sarah W @swashkowitz]

Southwest portion of Reservoir

[Sarah W @swashkowitz]

@atlanticgrill are your phones down? Can’t get through

[Immunomedics @ImmunomedicsInc]

This morning, Executive Chairman Dr. Behzad Aghazadeh discussed $IMMU's recent #FDAapproval and virtual launch plans to deliver our critical new therapy to people with #mTNBC during #COVID19 with @AlexisTVNews and @BrianSozzi on @YahooFinance’s “The First Trade’.

[Immunomedics @ImmunomedicsInc]

#ICYMI because you were appropriately socially distancing, our recent #FDAapproval of #TRODELVY received a shoutout on the Nasdaq building in @TimesSquareNYC! We hope for more wins like this for patients everywhere in the future. Thank you, @Nasdaq!

📸: Copyright Nasdaq 2020

[Aditya Bardia, MD @dradityabardia]

FDA granted approval to sacituzumab govitecan-hziy (Trodelvy) for mTNBC. Great news for the field & need to build on progress. In academics, it is said ‘we stand on shoulder of giants’. The giants in drug approval are pts in the trial. #bcsm #oncoalert https://t.co/dOZ5BKNN3q

[Immunomedics @ImmunomedicsInc]

Yesterday’s FDA approval underscores our commitment to bringing critical new therapies for hard-to-treat cancers. Learn more: https://t.co/NhNlZo3VNZ #mTNBC #TNBC #BreastCancer

[Immunomedics @ImmunomedicsInc]

Thank you to our IMMU colleagues whose hard work and commitment led to our first FDA approval! This milestone would not be possible without your efforts and dedication to people with #mTNBC.

[Immunomedics @ImmunomedicsInc]

We are excited to announce the @US_FDA approval of our critical new therapy in metastatic triple-negative breast cancer (#mTNBC). Learn more: https://t.co/NhNlZo3VNZ #CancerTreatment #metastatic #TNBC

[Immunomedics @ImmunomedicsInc]

Today, we announced that our Phase 3 confirmatory ASCENT study will be stopped due to compelling evidence of efficacy. Please read our full press release for more information: https://t.co/6thPZkzLbh. $IMMU

[Sarah W @swashkowitz]

@ridewithvia is the app down in NYC?

[Jane Lowe Meisel, MD @jane_meisel]

Promising data for sacituzumab in heavily pretreated metastatic ER+ breast cancer. Great presentation by @ABhealer108 at #ASCO18 ! #bcsm

[George W Sledge MD @GeorgeSledge51]

Oral breast session at #ASCO18: Sacituzumab govitecan ADC with SN-38 payload in ER-positive Her2-neg pts: 31% ORR and MDR of 7.4 mo. PFS data not yet mature.

[Roberto Leon-Ferre @rleonferre]

Sacituzumab also holds promise in refractory metastatic ER+HER2- breast cancer

[Prof Peter Hotez MD PhD DSc(hon) @PeterHotez]

NEW @TexasMonthly reports on my journey-battle-struggle to defend #science #vaccines #publichealth in #Texas (and... https://t.co/m3XeWdj4Hu

[Prof Peter Hotez MD PhD DSc(hon) @PeterHotez]

#NationalCatDay Deworm your pet: Toxocariasis now the leading human worm infection in the US; lung + CNS illness https://t.co/4gRsI6aXpA

[Prof Peter Hotez MD PhD DSc(hon) @PeterHotez]

Since 2016 I've written/spoken about how we're heading here in states with high nonmedical exemptions TX AZ WA OR ID https://t.co/lVr4H7CcuC

[Prof Peter Hotez MD PhD DSc(hon) @PeterHotez]

I do not see how this thing goes away on its own unless we take action now to stop #antivax movements in US Europe https://t.co/2CSJaMGsyp